Document Detail


Cardioprotective potential of annexin-A1 mimetics in myocardial infarction.
MedLine Citation:
PMID:  25460034     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Myocardial infarction (MI) and its resultant heart failure remains a major cause of death in the world. The current treatments for patients with MI are revascularization with thrombolytic agents or interventional procedures. These treatments have focused on restoring blood flow to the ischemic tissue to prevent tissue necrosis and preserve organ function. The restoration of blood flow after a period of ischemia, however, may elicit further myocardial damage, called reperfusion injury. Pharmacological interventions, such as antioxidant and Ca(2+) channel blockers, have shown premises in experimental settings; however, clinical studies have shown limited success. Thus, there is a need for the development of novel therapies to treat reperfusion injury. The therapeutic potential of glucocorticoid-regulated anti-inflammatory mediator annexin-A1 (ANX-A1) has recently been recognized in a range of systemic inflammatory disorders. ANX-A1 binds to and activates the family of formyl peptide receptors (G protein-coupled receptor family) to inhibit neutrophil activation, migration and infiltration. Until recently, studies on the cardioprotective actions of ANX-A1 and its peptide mimetics (Ac2-26, CGEN-855A) have largely focused on its anti-inflammatory effects as a mechanism of preserving myocardial viability following I-R injury. Our laboratory provided the first evidence of the direct protective action of ANX-A1 on myocardium, independent of inflammatory cells in vitro. We now review the potential for ANX-A1 based therapeutics to be seen as a "triple shield" therapy against myocardial I-R injury, limiting neutrophil infiltration and preserving both cardiomyocyte viability and contractile function. This novel therapy may thus represent a valuable clinical approach to improve outcome after MI.
Authors:
Chengxue Qin; Yuan H Yang; Lauren May; Xiaoming Gao; Alastair Stewart; Yan Tu; Owen L Woodman; Rebecca H Ritchie
Related Documents :
23604804 - Myocardial perfusion imaging after coronary revascularization: a clinical appraisal.
25420194 - Transplanted human amniotic epithelial cells secrete paracrine pro-angiogenic cytokines...
24686994 - Possible role of bnp for an early diagnosis of asymptomatic left ventricular dysfunctio...
23328564 - Single resting hstnt level predicts abnormal myocardial stress test in acute chest pain...
20486954 - Takotsubo cardiomyopathy induced by dobutamine infusion: a new phenomenon or an old dis...
2711384 - The response of normal and failing heart to externally applied vibration in the canine ...
Publication Detail:
Type:  REVIEW     Date:  2014-11-25
Journal Detail:
Title:  Pharmacology & therapeutics     Volume:  -     ISSN:  1879-016X     ISO Abbreviation:  Pharmacol. Ther.     Publication Date:  2014 Nov 
Date Detail:
Created Date:  2014-12-2     Completed Date:  -     Revised Date:  2014-12-3    
Medline Journal Info:
Nlm Unique ID:  7905840     Medline TA:  Pharmacol Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2014. Published by Elsevier Inc.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effects of using electronic cigarettes on nicotine delivery and cardiovascular function in compariso...
Next Document:  "Asthma is not only an airway disease, but also a vascular disease"